Novo Nordisk CEO Lars Fruergaard Jorgensen discusses plans to launch the weight-loss drug Wegovy in Europe this 12 months, increasing capex to spice up manufacturing, and the corporate attaining a $500 billion market worth.
——–
Follow Bloomberg for enterprise information & evaluation, up-to-the-minute market information, options, profiles and extra: http://www.bloomberg.com
Connect with us on…
Twitter: https://twitter.com/business
Facebook: https://www.facebook.com/bloombergbusiness
Instagram: https://www.instagram.com/bloombergbusiness/